ClinVar Miner

Submissions for variant NM_004453.4(ETFDH):c.1277A>G (p.Lys426Arg)

gnomAD frequency: 0.00011  dbSNP: rs200611086
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001279053 SCV001489532 uncertain significance Multiple acyl-CoA dehydrogenase deficiency 2022-02-09 criteria provided, single submitter clinical testing This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 426 of the ETFDH protein (p.Lys426Arg). This variant is present in population databases (rs200611086, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with ETFDH-related conditions. ClinVar contains an entry for this variant (Variation ID: 990933). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ETFDH protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002537827 SCV003532301 uncertain significance Inborn genetic diseases 2022-08-12 criteria provided, single submitter clinical testing The c.1277A>G (p.K426R) alteration is located in exon 10 (coding exon 10) of the ETFDH gene. This alteration results from a A to G substitution at nucleotide position 1277, causing the lysine (K) at amino acid position 426 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Natera, Inc. RCV001279053 SCV001466113 uncertain significance Multiple acyl-CoA dehydrogenase deficiency 2020-04-21 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.